NO991691L - Cancer immunoterapi ved Õ bruke tumorceller kombinert med blandede lymfosytter - Google Patents

Cancer immunoterapi ved Õ bruke tumorceller kombinert med blandede lymfosytter

Info

Publication number
NO991691L
NO991691L NO991691A NO991691A NO991691L NO 991691 L NO991691 L NO 991691L NO 991691 A NO991691 A NO 991691A NO 991691 A NO991691 A NO 991691A NO 991691 L NO991691 L NO 991691L
Authority
NO
Norway
Prior art keywords
tumor
stimulated
lymphocytes
allogeneic
cancer immunotherapy
Prior art date
Application number
NO991691A
Other languages
English (en)
Norwegian (no)
Other versions
NO991691D0 (no
Inventor
John C Hiserodt
James A Thompson
Gale A Granger
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO991691D0 publication Critical patent/NO991691D0/no
Publication of NO991691L publication Critical patent/NO991691L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO991691A 1996-10-11 1999-04-09 Cancer immunoterapi ved Õ bruke tumorceller kombinert med blandede lymfosytter NO991691L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2854896P 1996-10-11 1996-10-11
PCT/US1997/018718 WO1998016238A2 (fr) 1996-10-11 1997-10-10 Immunotherapie anticancereuse utilisant des cellules tumorales combinees a des lymphocytes mixtes

Publications (2)

Publication Number Publication Date
NO991691D0 NO991691D0 (no) 1999-04-09
NO991691L true NO991691L (no) 1999-06-09

Family

ID=21844058

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991691A NO991691L (no) 1996-10-11 1999-04-09 Cancer immunoterapi ved Õ bruke tumorceller kombinert med blandede lymfosytter

Country Status (13)

Country Link
US (1) US6207147B1 (fr)
EP (1) EP0930887B1 (fr)
JP (1) JP2001509135A (fr)
KR (1) KR20000049096A (fr)
CN (1) CN1237909A (fr)
AR (1) AR004445A1 (fr)
AT (1) ATE229810T1 (fr)
AU (1) AU743855B2 (fr)
BR (1) BR9712988A (fr)
CA (1) CA2267157C (fr)
DE (1) DE69718029T2 (fr)
NO (1) NO991691L (fr)
WO (1) WO1998016238A2 (fr)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203787B1 (en) 1997-10-10 2001-03-20 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US20080220025A1 (en) * 1995-03-17 2008-09-11 James Thompson Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells
WO1998048000A2 (fr) * 1997-04-23 1998-10-29 The Regents Of The University Of California Souche cellulaire a activite cytotoxique anticancereuse
AU9794698A (en) * 1997-10-10 1999-05-03 Regents Of The University Of California, The Enhanced immunogenic cell populations prepared using h2 receptor antagonists
WO1999018980A1 (fr) 1997-10-10 1999-04-22 Meyer Pharmaceuticals, Llc Immunotherapie du cancer utilisant des cellules allostimulees dans une strategie de greffe sequentielle multiple
JP4389039B2 (ja) * 1998-04-09 2009-12-24 株式会社リンフォテック アロジェニックな活性化ｃｄ４陽性細胞を主成分とする医薬組成物、およびその製造方法、ならびに該医薬組成物調製用キット
US7666609B1 (en) 1998-12-01 2010-02-23 Shanghai Cp Guojian Pharmaceutical Co. Ltd. Method and composition for diagnosis of melanocytic lesions
CA2362578A1 (fr) * 1999-02-09 2000-08-17 Kam Leong Vaccins anti-tumeurs
DK1272617T3 (da) 2000-04-01 2011-08-22 Onyvax Ltd Prostata cellelinier og deres anvendelse
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
DE10043437A1 (de) * 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US20040191246A1 (en) 2003-02-26 2004-09-30 Connelly Patrick R. Process for in vivo treatment of specific biological targets in bodily fluid
US7723111B2 (en) * 2001-03-09 2010-05-25 The United States Of America As Represented By The Department Of Health And Human Services Activated dual specificity lymphocytes and their methods of use
JP4916641B2 (ja) * 2001-05-11 2012-04-18 ウェルスタット バイオロジクス コーポレイション 腫瘍崩壊性ウイルス治療
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
EP1293205A1 (fr) * 2001-09-18 2003-03-19 G2M Cancer Drugs AG Acide valproique et ses dérivés pour la polythérapie du cancer humain et pour le traitement de la métastase de tumeurs et de la maladie residuelle imperceptible
ATE386129T1 (de) * 2001-11-27 2008-03-15 Nexyte Ab Produktion eukaryontischer proteine und nukleinsäuremoleküle in c. elegans
KR20020060643A (ko) * 2002-06-04 2002-07-18 김진경 타인의 면역시스템을 이용하는 암의 치료 방법
BRPI0305769A8 (pt) * 2002-08-08 2017-09-12 Baylor College Medicine Isolamento e identificação de células t
US7571817B2 (en) * 2002-11-06 2009-08-11 Varco I/P, Inc. Automatic separator or shaker with electromagnetic vibrator apparatus
WO2004096244A1 (fr) * 2003-05-02 2004-11-11 Md Bioalpha Co. Ltd. Procede de preparation d'un vaccin pour induire une activite antitumorale et composition pharmaceutique le comprenant
JP5049011B2 (ja) 2003-06-11 2012-10-17 ザ ユニバーシティー オブ シカゴ 変異体ｌｉｇｈｔによるｔ細胞腫瘍浸潤の増大
US7811983B2 (en) * 2003-06-11 2010-10-12 The University Of Chicago Increased T-cell tumor infiltration and eradication of metastases by mutant light
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
NZ597965A (en) * 2003-10-08 2013-09-27 Vet Stem Inc Methods of preparing and using stem cell compositions and kits comprising the same
US8029454B2 (en) 2003-11-05 2011-10-04 Baxter International Inc. High convection home hemodialysis/hemofiltration and sorbent system
US20050112684A1 (en) * 2003-11-21 2005-05-26 Eric Holzle Class I and Class II MHC Profiling for Social and Sexual Matching of Human Partners
CN1950518A (zh) 2004-02-03 2007-04-18 密执安州立大学董事会 表征、调节、诊断和治疗癌症的组合物和方法
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
US9155789B2 (en) * 2005-04-25 2015-10-13 New York University Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease
US20090162405A1 (en) * 2006-12-14 2009-06-25 Yong Qian Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells
US8778362B2 (en) 2005-10-27 2014-07-15 University Of Notre Dame Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
US8802113B2 (en) * 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8778360B2 (en) * 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US9308252B2 (en) * 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
ES2547421T3 (es) 2005-10-31 2015-10-06 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para diagnosticar y tratar el cáncer
WO2007053648A2 (fr) * 2005-10-31 2007-05-10 The Regents Of The University Of Michigan Compositions et méthodes pour traiter et diagnostiquer un cancer
US20070243192A1 (en) * 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
US20080019961A1 (en) * 2006-02-21 2008-01-24 Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
ES2553192T3 (es) * 2006-05-05 2015-12-04 Opexa Therapeutics Vacuna de células T
PL2511301T3 (pl) 2006-08-04 2018-05-30 Medimmune Limited Ludzkie przeciwciała do ErbB2
US7972594B2 (en) 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
US8691568B2 (en) * 2006-11-22 2014-04-08 Hua Liu Method for preparing cell populations with anti-tumor immune response activity
US20080147007A1 (en) * 2006-12-19 2008-06-19 Toby Freyman Delivery device with pressure control
EP2106439B1 (fr) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions et procédés pour le traitement et le diagnostic du cancer du pancréas
EP2117305A4 (fr) * 2007-01-26 2011-03-30 Univ Louisville Res Found Modification de composants à base d' exosome utilisés comme vaccin
US20090093429A1 (en) * 2007-02-08 2009-04-09 Yang-Xin Fu Combination therapy for treating cancer
WO2008144029A1 (fr) 2007-05-14 2008-11-27 The University Of Chicago Produits de fusion anticorps-light pour les thérapies du cancer
US8741315B2 (en) * 2007-09-12 2014-06-03 Yeda Research And Development Co. Ltd. Methods of treating tumors in immune-privileged sites
US8114276B2 (en) 2007-10-24 2012-02-14 Baxter International Inc. Personal hemodialysis system
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
WO2010051502A2 (fr) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Molécules ciblant light et leurs utilisations
BRPI0921150B1 (pt) 2008-11-11 2022-05-10 The Regents Of The University Of Michigan Uso de um antagonista de cxcr1 para o tratamento de tumor
CU23740A1 (es) * 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
CN102597222B (zh) * 2009-10-27 2015-07-15 因缪尼卡姆股份公司 用于增殖抗原特异性t细胞的方法
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
AU2010341703B2 (en) * 2009-12-08 2016-01-21 The Board Of Trustees Of The University Of Illinois Stem cell immune modulation methods of use and apparatus
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011116209A2 (fr) 2010-03-17 2011-09-22 The Regents Of The University Of Michigan Utilisation d'épitopes de phage à des fins de profilage de la réponse immunitaire
AU2011235904B2 (en) 2010-04-01 2015-10-08 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2011129348A1 (fr) * 2010-04-13 2011-10-20 株式会社Ｒｅｉメディカル Composition pour le traitement du cancer, qui est produite à partir d'une masse cellulaire p ou d'un agrégat de cellules cancéreuses, et procédé de production d'un agent immunothérapeutique et procédé d'évaluation de l'efficacité de l'immunothérapie utilisant tous deux la composition
JP5934783B2 (ja) * 2011-05-03 2016-06-15 イミュノバティブ セラピーズ，リミテッド 生細胞を含む生物学的薬剤の取り扱い方法
AU2012261237B2 (en) * 2011-05-24 2017-06-01 BioNTech SE Individualized vaccines for cancer
EP2790730B1 (fr) 2011-12-15 2019-01-23 The University of Chicago Méthodes et compositions destinés au traitement du cancer utilisant des molécules light mutantes ayant une affinité accrue pour les récepteurs
US9266959B2 (en) 2012-10-23 2016-02-23 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using frizzled-binding agents
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
KR20160089356A (ko) * 2013-09-27 2016-07-27 백시노젠 인터내셔널 파트너스, 엘피 자가 종양 백신 및 방법
BR112017009475B1 (pt) 2014-11-05 2021-10-05 Memorial Sloan Kettering Cancer Center Métodos de seleção de uma linhagem de células t e de um doador das mesmas, sistema de computador para selecionar uma linhagem de células t, meio legível por computador, uso de uma população de células t e método para a obtenção de uma linhagem de células t
WO2016145292A1 (fr) * 2015-03-12 2016-09-15 University Of Iowa Research Foundation Vaccin, composition thérapeutique et méthodes pour traiter ou inhiber le cancer
EP3313419B1 (fr) * 2015-06-26 2020-08-19 Memorial Sloan Kettering Cancer Center Procédés de traitement de la rétinite à cytomégalovirus (cmv) par thérapie à lymphocytes t
CN108472314A (zh) 2015-07-31 2018-08-31 明尼苏达大学董事会 修饰的细胞和治疗方法
US11219645B2 (en) 2015-11-18 2022-01-11 Duke University Tumor infiltrating lymphocytes for treatment of cancer
EP4338799A3 (fr) 2016-10-18 2024-06-05 Regents of the University of Minnesota Lymphocytes infiltrant les tumeurs et procédés de thérapie
US20200237904A1 (en) 2017-01-26 2020-07-30 Immune Therapeutics Inc. Methods and Compositions Useful for Treating Cancer
WO2019006418A2 (fr) 2017-06-30 2019-01-03 Intima Bioscience, Inc. Vecteurs viraux adéno-associés destinés à la thérapie génique
KR102256337B1 (ko) * 2017-10-17 2021-05-26 (주)노터스생명과학 조직이식을 위한 세포배양액을 포함하는 면역억제제
US11446329B2 (en) 2017-11-01 2022-09-20 Restem Llc Natural killer cell adoptive transfer therapy for the elimination of senescent PBMCs, reduction of inflammatory cytokines and treatment of IBS
IL259392A (en) 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neo-antigens
FR3082730B1 (fr) * 2018-06-21 2022-04-22 Med Inn Pharma Methode de resolution de l'inflammation pro-tumorale a l'aide d'une preparation pharmaceutique
WO2023196232A1 (fr) * 2022-04-04 2023-10-12 University Of Florida Research Foundation, Inc. Méthode de caractérisation de tumeurs
CN114984199A (zh) * 2022-04-19 2022-09-02 苏州尔生生物医药有限公司 一种基于癌症特异性t细胞的细胞系统、淋巴细胞药物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192537A (en) 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
JP2639835B2 (ja) * 1988-11-30 1997-08-13 有限会社ジオリサーチ 免疫記憶細胞懸濁液の調製方法
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
JPH06121672A (ja) * 1992-10-13 1994-05-06 Cellcor Inc 免疫反応性細胞の製造
US5820872A (en) * 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
WO1994020120A1 (fr) 1993-03-12 1994-09-15 Cellcor, Inc. Methode de titrage in vitro pour la mesure du degre d'activation de cellules immunes
EP0734440A1 (fr) 1993-12-14 1996-10-02 Yajun Guo Fusions de cellules tumorales et procedes d'utilisation de telles fusions de cellules tumorales
US5759535A (en) 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer
EP0765386B1 (fr) * 1994-06-14 2014-12-10 The Board Of Trustees Of The Leland Stanford Junior University Procedes pour l'activation de lymphocytes t in vivo par des cellules dendritiques a impulsions antigeniques
DE4431401A1 (de) 1994-08-24 1996-02-29 Max Delbrueck Centrum Lebendvakzine gegen Tumorerkrankungen
JP3201610B2 (ja) * 1995-03-17 2001-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍を処置する方法
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine

Also Published As

Publication number Publication date
AU743855B2 (en) 2002-02-07
BR9712988A (pt) 2000-10-24
ATE229810T1 (de) 2003-01-15
DE69718029T2 (de) 2003-10-16
JP2001509135A (ja) 2001-07-10
NO991691D0 (no) 1999-04-09
DE69718029D1 (de) 2003-01-30
EP0930887B1 (fr) 2002-12-18
WO1998016238A2 (fr) 1998-04-23
AR004445A1 (es) 1998-12-16
US6207147B1 (en) 2001-03-27
EP0930887A2 (fr) 1999-07-28
AU4824297A (en) 1998-05-11
CA2267157A1 (fr) 1998-04-23
KR20000049096A (ko) 2000-07-25
CA2267157C (fr) 2005-05-31
CN1237909A (zh) 1999-12-08
WO1998016238A3 (fr) 1998-09-11

Similar Documents

Publication Publication Date Title
NO991691L (no) Cancer immunoterapi ved Õ bruke tumorceller kombinert med blandede lymfosytter
Zhivaki et al. Inflammasomes within hyperactive murine dendritic cells stimulate long-lived T cell-mediated anti-tumor immunity
EP0789574A4 (fr) Procedes et dispositifs destines a immuniser un hote d'antigenes associes a une tumeur par l'administration de polynucleotides nus codant des peptides antigeniques associes a une tumeur
ATE472339T1 (de) Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
ATE389712T1 (de) Krebs immuntherapie mit semi-allogenen zellen
He et al. Antitumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatous mouse
Zhang et al. Impact of dose, route, and composition on the immunogenicity of immune polyelectrolyte multilayers delivered on gold templates
Van Dinther et al. Comparison of protein and peptide targeting for the development of a CD169-based vaccination strategy against melanoma
Gregoire et al. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia
Escribà-Garcia et al. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma
US20100092499A1 (en) Alpha Thymosin Peptides as Cancer Vaccine Adjuvants
WO2003033520A3 (fr) Vaccin anticancereux, methodes diagnostiques et reactifs
Schultes et al. Monitoring of immune responses to CA125 with an IFN-γ ELISPOT assay
EP1229936B1 (fr) Utilisation d'anticorps anti-idiotypiques en tant que vaccins contre le cancer
Wagner et al. Induction and characterization of anti-tumor endothelium immunity elicited by ValloVax therapeutic cancer vaccine
Grzybowski et al. Novel dual arginase 1/2 inhibitor OATD-02 (OAT-1746) improves the efficacy of immune checkpoint inhibitors
Durrant et al. Cancer vaccines entering Phase III clinical trials
CN111372656A (zh) 抗体依赖性细胞介导的细胞毒性(adcc)的增强
Bolli et al. Oncoantigens for an immune prevention of cancer
Shimada et al. TNP-specific Lyt-2+ cytolytic T cell clones preferentially respond to TNP-conjugated epidermal cells.
Prat et al. Monoclonal antibodies against murine IFN-gamma abrogate in vivo tumor immunity against RSV-induced murine sarcomas.
Schütz et al. MHC‐Ig induces memory T cell formation in vivo and inhibits tumour growth
Jin et al. The Epitope Basis of Embryonic Stem Cell‐Induced Antitumor Immunity against Bladder Cancer
Takai et al. TT cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
Isakov et al. An immunoregulatory factor associated with spleen cells from tumor‐bearing animals. I. Effect on tumor growth and antibody production

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application